1.10

1.38% 0.01

Rapt Therapeutics Inc (RAPT)

Overview News Price History Option Chain Financials Discussions Forecast

Rapt Therapeutics Inc stock is traded at $1.10, with a volume of 155.96K. It is up +1.38% in the last 24 hours and down -6.36% over the past month. RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Previous Close:

$1.09

Open:

$1.07

24h Volume:

155.96K

Relative Volume:

0.05

Market Cap:

$143.89M

Revenue:

$3.25M

Net Income/Loss:

$-116.80M

P/E Ratio:

-0.3607

EPS:

-3.05

Net Cash Flow:

$-98.17M

1W Performance:

-11.60%

1M Performance:

-6.36%

6M Performance:

-51.32%

1Y Performance:

-87.24%

1-Day Range:

$1.07

$1.14

1-Week Range:

$1.07

$1.28

52-Week Range:

$0.7893

$10.05

Rapt Therapeutics Inc Stock (RAPT) Company Profile

Name

Rapt Therapeutics Inc

Sector

Healthcare (1189)

Industry

Biotechnology (675)

Phone

(650) 489-9000

Address

561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

RAPT's Discussions on Twitter

Compare RAPT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RAPT Rapt Therapeutics Inc	1.1065	143.89M	3.25M	-116.80M	-98.17M	-3.05
VRTX Vertex Pharmaceuticals Inc	477.45	121.85B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	698.03	76.83B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	618.58	37.96B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	242.53	30.69B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	269.23	29.71B	3.32B	-860.46M	-1.04B	-8.32

Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-26-24	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-13-24	Downgrade	Stifel	Buy → Hold
Nov-11-24	Downgrade	JP Morgan	Neutral → Underweight
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
May-14-24	Downgrade	Wolfe Research	Outperform → Peer Perform
May-10-24	Downgrade	Barclays	Overweight → Equal Weight
May-10-24	Downgrade	Guggenheim	Buy → Neutral
Feb-22-24	Downgrade	UBS	Buy → Neutral
Feb-21-24	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-21-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-21-24	Downgrade	Leerink Partners	Outperform → Market Perform
Feb-20-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-16-24	Initiated	Evercore ISI	Outperform
Feb-15-24	Initiated	Wolfe Research	Outperform
Sep-14-23	Initiated	Berenberg	Buy
Aug-09-23	Initiated	Stifel	Buy
Jun-15-23	Initiated	Barclays	Overweight
Jan-04-23	Initiated	Guggenheim	Buy
Dec-01-22	Initiated	Goldman	Buy
Sep-21-22	Initiated	CapitalOne	Overweight
May-24-22	Resumed	Cantor Fitzgerald	Overweight
Dec-09-21	Initiated	JP Morgan	Overweight
Aug-12-21	Initiated	SVB Leerink	Outperform
Jun-21-21	Initiated	Piper Sandler	Overweight
Jun-01-20	Initiated	H.C. Wainwright	Buy
May-19-20	Initiated	Cantor Fitzgerald	Overweight
Apr-13-20	Initiated	ROTH Capital	Buy
Nov-25-19	Initiated	BMO Capital Markets	Outperform
Nov-25-19	Initiated	UBS	Buy
Nov-25-19	Initiated	Wells Fargo	Outperform

View All

Rapt Therapeutics Inc Stock (RAPT) Latest News

Feb 27, 2025

RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday - Defense World

Feb 27, 2025

Feb 23, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts - Defense World

Feb 23, 2025

Feb 16, 2025

Still Cautious Over RAPT Therapeutics’ Fresh Start With RPT904 (NASDAQ:RAPT) - Seeking Alpha

Feb 16, 2025